|
Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amal Therapeutics; Amgen; Bayer; Sanofi |
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi |
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Incyte; Lilly; Merck Serono; SERVIER |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Pierre Fabre; Roche; Servier |
Research Funding - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai; incyte; Lilly |
Speakers' Bureau - Clovis Oncology |
Research Funding - Lilly (Inst); Roche (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Celgene; Ipsen; Roche; Sanofi; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Eisai; Merck; MSD; Sanofi |
Speakers' Bureau - Amgen; Bayer; Eisai; Merck; MSD; Sanofi |